MRNA - CIK 0001682852
Moderna, Inc. (MRNA) reported net income of -$2.82B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$2.82B | +20.8% |
| FY 2024 | -$3.56B | +24.5% |
| FY 2023 | -$4.71B | -156.4% |
| FY 2022 | $8.36B | -31.5% |
| FY 2021 | $12.20B | +1733.5% |
| FY 2020 | -$747.00M | -45.3% |
| FY 2019 | -$514.00M | -33.6% |
| FY 2018 | -$384.73M | -50.3% |
| FY 2017 |
Moderna, Inc. (MRNA) reported net income of -$2.82B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Moderna, Inc.'s net income declined from -$216.21M to -$2.82B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$255.92M |
| -18.4% |
| FY 2016 | -$216.21M | - |